Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Launches Similac? 360 Total Care? with Exclusive Blend of Five Hmo Prebiotics and Designed to Support the Immune System, Digestive Health and Brain Development

11/16/2021 | 01:00pm EST

Abbott announced the launch of Similac 360 Total Care, the company's next generation of infant formula with HMOs, major prebiotics structurally identical to those found in human breast milk. Similac 360 Total Care is the first and only infant formula in the U.S. with a blend of five different HMOs, previously only found together in breast milk. This formula is designed to provide nutrition to support the whole baby's health and development, including the developing immune system, digestive system and brain. Abbott scientists have been studying HMOs in breast milk for more than two decades. While breast milk is the gold standard of infant nutrition, nearly 75% of parents introduce infant formula within the first six months of a baby's life for a variety of reasons. Abbott supports parents, whatever their feeding choice. Now with the introduction of Similac 360 Total Care, parents can use a formula with a blend of five specific HMOs, previously only available to infants through breast milk. The introduction of Similac 360 Total Care is part of Abbott's ongoing commitment to support health from infancy onward. Through ongoing research, investment and innovation, this commitment supports Similac's Promises Project, the promise to support all parents regardless of their feeding choices.


ę S&P Capital IQ 2021
All news about ABBOTT LABORATORIES
01/18Abbott Unit Wins $306 Million Contract to Provide COVID-19 Rapid Test Kits to US Army
MT
01/13ABBOTT LABORATORIES : Ex-dividend day for
FA
01/12Health Care Down On Cyclical Bias -- Health Care Roundup
DJ
01/12Abbott Laboratories Secures FDA Clearance for Ensite Cardiac Mapping Platform
MT
01/12Abbott Labs Gets U.S. Clearance For Heart Mapping Platform
DJ
01/12Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctor..
PR
01/12Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctor..
CI
01/11ABBOTT LABS CEO : Opportunity Exists to do More in Share Buybacks, Looking Closely at M&A ..
MT
01/11Abbott Laboratories Exec Says Expect Covid-19 Testing Demand Strength To Continue In Th..
RE
01/11Abbott laboratories exec says expect covid-19 testing demand strength to continue in th..
RE
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2021 42 172 M - -
Net income 2021 6 738 M - -
Net Debt 2021 8 198 M - -
P/E ratio 2021 33,3x
Yield 2021 1,36%
Capitalization 216 B 216 B -
EV / Sales 2021 5,32x
EV / Sales 2022 5,48x
Nbr of Employees 109 000
Free-Float -
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 126,05 $
Average target price 142,01 $
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Robert B. Ford Chairman, President, Chief Executive Officer & COO
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Roxanne Schuh Austin Independent Director
Glenn Fletcher Tilton Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES-10.44%217 064
MEDTRONIC PLC4.93%144 527
BECTON, DICKINSON AND COMPANY4.43%74 231
HOYA CORPORATION-6.78%51 355
BAXTER INTERNATIONAL INC.0.02%42 990
DEXCOM, INC.-19.94%41 664